Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Cel-SciEli Lilly
Last price
$1.38$1,417.54
Currency
USD
USD
$26M$1.3T
-46.01
-$2.57$30.81
0.560.45
0$6.69
00.49%
Sector
HealthHealth
Employees
4450,000
Ticker
$CVM$LLY
Primary listing
AMEXNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $CVM or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.